Stockscreener 앱 받기
1.12
2.61%
-0.03
시간 외 거래:
1.11
-0.01
-0.89%
전일 마감가:
$1.15
열려 있는:
$1.15
하루 거래량:
486.90K
Relative Volume:
1.42
시가총액:
$28.56M
수익:
-
순이익/손실:
$-8.09M
주가수익비율:
-2.5723
EPS:
-0.4354
순현금흐름:
$-7.37M
1주 성능:
-9.68%
1개월 성능:
-26.32%
6개월 성능:
+17.13%
1년 성능:
-18.55%
1일 변동 폭
$1.10
$1.17
1주일 범위
$1.10
$1.33
52주 변동 폭
$0.85
$2.2299
NanoViricides Inc Stock (NNVC) Company Profile
명칭
NanoViricides Inc
전화
203-937-6137
주소
1 Controls Drive, Shelton, CT
Compare NNVC vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NNVC
NanoViricides Inc
|
1.12 | 33.40M | 0 | -8.09M | -7.37M | -0.4354 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
NanoViricides Inc Stock (NNVC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-16 | 개시 | Alliance Global Partners | Buy |
| 2015-02-11 | 개시 | Midtown Partners | Strong Buy |
NanoViricides Inc 주식(NNVC)의 최신 뉴스
While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles - ACCESS Newswire
NNVC Stock In The Limelight After This Analyst Sees A 350% Upside Potential – Everything To Know About Its Experimental Drug For Ebola - Stocktwits
Nanoviricides Stock Price Forecast. Should You Buy NNVC? - StockInvest.us
NanoViricides (AMEX: NNVC) May Generate Up to $4.4 Million Through Warrant Exercises - Kalkine Media
US FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for MeaslesEnables Priority Review Voucher - ACCESS Newswire
U.S. measles cases reach 2,903 by Aug. 27 as NanoViricides prepares a trial - Stock Titan
NanoViricides Inc. (NNVC) Financials – Balance Sheet, Profit & Loss, Cash Flow - valueresearchonline.com
NanoViricides (NNVC) Chart: Ends Lower by 3.08% at $1.29 in the Latest Session; Technical View: the Supplied Trading Band Runs From $1.23 to $1.35 in the Available RecordFibonacci Fan - vinanet.vn
NanoViricides (NNVC) Technicals: Ends Up by 1.53% at $1.33 in the Latest Reading; Immediate View: Support at $1.26 and Resistance at $1.40 Frame the Range in the Available RecordWyckoff Accumulation - vinanet.vn
NanoViricides (NYSE American: NNVC) sets up warrant resale, up to $4.4M cash - Stock Titan
NanoViricides (NNVC) Levels: Finishes 0.82% Down at $1.33 at the Close; Chart Watch: Traders Can Monitor the $1.26-$1.40 Range in the Current UpdateHigh Conviction Picks - vinanet.vn
NanoViricides Prepares for Phase II Ebola Trial of Oral Drug Candidate in DRC - citybuzz -
Ebola outbreak has killed 2,325 as oral drug trial nears - Stock Titan
NNVC Stock Up 17% Today: What’s Driving The Rally? - Stocktwits
ETFs Investing in NanoViricides, Inc. Stocks - TradingView
NNVC Q2 2026 Earnings: EPS Surprise of 22.97% Bolsters Sentiment as Shares Rise 1.47%Interim Report - vinanet.vn
NNVC Q2 2026 Earnings: Narrower-Than-Expected Loss Marks 22.97% Positive SurpriseQuarterly Earnings Report - vinanet.vn
NanoViricides (NNVC) Edges Lower to $1.36 as Antiviral Developer Holds Support ZoneNews Sentiment - vinanet.vn
NanoViricides (NNVC) Slips to $1.36 as Biotech Micro-Cap Tests Key Support ZoneImpulse Wave - vinanet.vn
NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak - ACCESS Newswire
NanoViricides (NNVC) Dips 2.5% to $1.36 as Shares Approach Critical $1.29 SupportCollar Trade - vinanet.vn
NanoViricides, Inc. (NNVC) Stock Price, News, Quote & History - Yahoo! Finance Canada
NanoViricides Gets Approval for Phase II Ebola Trial in DRC, Offering Oral Treatment Option - citybuzz -
NanoViricides wins DRC approval for Phase II trial of NV-387 oral gummies for Ebola treatment - Bitget
DRC Ebola Outbreak Stands at 4,141 Cases as Oral Trial Gets Approval - Stock Titan
NNVC Q2 2026 Earnings: Loss Narrower Than Expected at -$0.11 Per Share, Stock Slips 2.1%Pre-Announcement Alert - vinanet.vn
NanoViricides (NNVC) Holds Gains at $1.54 as Shares Consolidate Between Support and ResistanceSweep Order Flow - vinanet.vn
NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close - Watertown Public Opinion
NanoViricides (NNVC) Q2 2026 Earnings: Narrower-Than-Expected Loss but Shares Slip 1.94%Dividend Earnings Report - vinanet.vn
NanoViricides Inc (NNVC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
NanoViricides Announces $3.8 Million Registered Direct Offering - TipRanks
NanoViricides Raises $3.8 Million in Registered Direct Offering; Adds Placement Agent and 30-Day Lock-Up - TradingView
Ebola outbreak death toll tops 1,300 as drug trial awaits approval - Stock Titan
NanoViricides Seeks Regulatory Approval for Ebola Trial of NV-387 Oral Gummies in DRC - citybuzz -
NanoViricides Inc (NNVC) Cash Flow - TradingKey
EDGAR Filing Documents for 0001104659-26-086797 - SEC.gov
Form 424B5 NanoViricides Inc For: 27 July By Investing.com - Investing.com Canada
Form 424B5 NANOVIRICIDES, INC. - StreetInsider
NanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering - ACCESS Newswire
As Ebola Death Toll Surpasses 930 Within Two Months, NanoViricides Has Applied to the DR Congo Regulatory Agency for Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola - ACCESS Newswire
NanoViricides, Inc. Revenue Breakdown – AMEX:NNVC - TradingView
NanoViricides Inc (NNVC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
NNVC|NanoViricides Inc|Price:1.535|Chg%:+0.055 - TradingKey
NanoViricides Inc (NNVC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NanoViricides Inc (NNVC) Institutional Confidence - TradingKey
NanoViricides Raises $3.8 Million in Registered Direct Offering to Fund Antiviral Drug Development - citybuzz -
NanoViricides Seeks Approval for Phase II Ebola Trial in DRC Amid Ongoing Outbreak - citybuzz -
NanoViricides (NYSE:NNVC) Draws Attention After Clinical Update - Kalkine Media
DRC Ebola outbreak tops 930 deaths; NanoViricides seeks trial approval - Stock Titan
NanoViricides Seeks Approval for Ebola Treatment Trial - AllSci
Nanoviricides Company Profile & Introduction - Moomoo
NanoViricides Inc (NNVC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.86%
0.31%
자본화:
|
볼륨(24시간):